Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
Harpoon Therapeutics (NASDAQ: HARP) announced that Dr. Gerald McMahon, CEO, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 4:20 p.m. ET. The event will be accessible via live audio webcast through the Investors section of Harpoon's website. Harpoon Therapeutics is focused on developing innovative T cell engagers to harness the immune system for cancer treatment, utilizing their TriTAC platform and currently advancing multiple clinical trials targeting various cancers.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference. The discussion will take place on Wednesday, February 24, 2021 at 4:20 p.m. ET (1:20 p.m. PT).
A live audio webcast of the fireside chat will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com with an archived replay available following the event.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Contacts:
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com
Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
FAQ
When is Harpoon Therapeutics' fireside chat at the SVB Leerink conference?
Who will represent Harpoon Therapeutics at the conference?
Where can I watch the Harpoon Therapeutics webcast?
What is Harpoon Therapeutics focused on developing?
What is the primary platform used by Harpoon Therapeutics?
